<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00467311</url>
  </required_header>
  <id_info>
    <org_study_id>07552</org_study_id>
    <nct_id>NCT00467311</nct_id>
  </id_info>
  <brief_title>Cystatin C as an Early Marker of Contrast-Medium Nephropathy in Cardiac Catheterization Patients</brief_title>
  <official_title>Diagnostic, Transversal, Comparative, Not Randomized Trial for the Evaluation of Cystatin C as an Early Marker of Contrast-Medium Nephropathy in High-and-Intermedium-Risk Patients Undergoing to Cardiac Catheterization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart Institute, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Heart Institute, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:

      Cystatin C compared with creatinine is a better and earlier marker of contrast-induced
      nephropathy in high and intermedium risk cardiac catheterization patients.

      Primary Objective:

      Establish if Cystatin C is superior detecting contrast-induced nephropathy than creatinine in
      high and intermedium risk cardiac catheterization patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Contrast induced-nephropathy is a complication that is underestimated in clinical practice
      after cardiac catheterization. During the last 30 years, because of the increasing use of
      contrast medium for diagnostic and therapeutic procedures, this has become the third
      in-hospital cause of acute renal failure (12%). That's why, it is necessary to establish an
      earlier marker of renal dysfunction that can help us in the diagnosis and allow us to
      initiate the appropriate therapeutics, because depending on the severity of the renal damage,
      it can increase the cardiovascular risk and morbidity.

      The risk of contrast medium nephropathy is still present even with the use of low osmolarity
      contrast media, and many patients increase their in-hospital days, costs and hemodialysis
      requirement.

      Cystatin C is a non glucosylated protein produced in nucleated cells in a constant rate, and
      because of its low molecular weight it's filtered through the glomerular membrane without
      restriction and it's fully reabsorbed in the proximal tubule, that's why it's considered an
      excellent marker evaluating the glomerular filtration rate in patients with acute renal
      failure during the first 24-48 hours.

      We propose that Cystatin C can be useful as an earlier and superior marker of
      contrast-induced nephropathy in high and intermedium cardiac catheterization patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <enrollment type="Actual">66</enrollment>
  <condition>Contrast Induced Nephropathy</condition>
  <condition>Acute Renal Failure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients over 20 years old with an indication for coronariography and/or percutaneous
        coronary intervention, and with a MEHRAN contrast-induced nephropathy score from six to
        fifteen.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 20 years old

          -  Indication for coronariography and/or percutaneous coronary intervention

          -  Voluntary written consent for the realization of coronariography and/or percutaneous
             intervention and for the participation in this clinical trial

          -  A MEHRAN contrast-induced nephropathy score from six to fifteen.

        Exclusion Criteria:

          -  N-Acetylcystein and Fenoldopam pre-medication

          -  Low risk patients according MEHRAN classification

          -  Cardiogenic and septic shock

          -  Acute renal failure by any other cause

          -  Patients with chronic kidney failure requiring any kind of dialysis

          -  Patients unable to complete follow-up

          -  Exposure to contrast media 48 hours prior to study

          -  Patients unable to give consent

          -  Receiving contrast media other than non-ionic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jhonathan L Uribe-González, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ignacio Chávez National Institute of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge G Hernández, MD, FSCAI</last_name>
    <role>Study Chair</role>
    <affiliation>Ignacio Chávez National Institute of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco A Martínez-Rios</last_name>
    <role>Study Director</role>
    <affiliation>Ignacio Chávez National Institute of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco A Peña-Duque, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ignacio Chávez National Institute of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ignacio Chávez National Institute of Cardiology</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <zip>01480</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.cardiologia.org.mx</url>
    <description>National Institute of Cardiology</description>
  </link>
  <reference>
    <citation>Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005 May 24;172(11):1461-71. Review. Erratum in: CMAJ. 2005 Nov 8;173(10):1210.</citation>
    <PMID>15911862</PMID>
  </reference>
  <reference>
    <citation>Rickli H, Benou K, Ammann P, Fehr T, Brunner-La Rocca HP, Petridis H, Riesen W, Wüthrich RP. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol. 2004 Feb;61(2):98-102.</citation>
    <PMID>14989628</PMID>
  </reference>
  <reference>
    <citation>Schück O, Teplan V, Jabor A, Stollova M, Skibova J. Glomerular filtration rate estimation in patients with advanced chronic renal insufficiency based on serum cystatin C levels. Nephron Clin Pract. 2003;93(4):c146-51.</citation>
    <PMID>12759583</PMID>
  </reference>
  <reference>
    <citation>Han WK, Bonventre JV. Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care. 2004 Dec;10(6):476-82. Review.</citation>
    <PMID>15616389</PMID>
  </reference>
  <reference>
    <citation>Villa P, Jiménez M, Soriano MC, Manzanares J, Casasnovas P. Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients. Crit Care. 2005 Apr;9(2):R139-43. Epub 2005 Feb 7.</citation>
    <PMID>15774046</PMID>
  </reference>
  <reference>
    <citation>Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005 May 19;352(20):2049-60.</citation>
    <PMID>15901858</PMID>
  </reference>
  <reference>
    <citation>Lameire N, Hoste E. Reflections on the definition, classification, and diagnostic evaluation of acute renal failure. Curr Opin Crit Care. 2004 Dec;10(6):468-75. Review.</citation>
    <PMID>15616388</PMID>
  </reference>
  <reference>
    <citation>Loew M, Hoffmann MM, Koenig W, Brenner H, Rothenbacher D. Genotype and plasma concentration of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events. Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1470-4. Epub 2005 Apr 28.</citation>
    <PMID>15860739</PMID>
  </reference>
  <reference>
    <citation>Mares J, Stejskal D, Vavrousková J, Urbánek K, Herzig R, Hlustík P. Use of cystatin C determination in clinical diagnostics. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2003 Dec;147(2):177-80. Review.</citation>
    <PMID>15037900</PMID>
  </reference>
  <reference>
    <citation>Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003 Oct;18(10):2024-31.</citation>
    <PMID>13679476</PMID>
  </reference>
  <reference>
    <citation>Bökenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C--a new marker of glomerular filtration rate in children independent of age and height. Pediatrics. 1998 May;101(5):875-81.</citation>
    <PMID>9565418</PMID>
  </reference>
  <reference>
    <citation>Herget-Rosenthal S, Marggraf G, Hüsing J, Göring F, Pietruck F, Janssen O, Philipp T, Kribben A. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004 Sep;66(3):1115-22.</citation>
    <PMID>15327406</PMID>
  </reference>
  <reference>
    <citation>Coll E, Botey A, Alvarez L, Poch E, Quintó L, Saurina A, Vera M, Piera C, Darnell A. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000 Jul;36(1):29-34.</citation>
    <PMID>10873868</PMID>
  </reference>
  <reference>
    <citation>O'Riordan SE, Webb MC, Stowe HJ, Simpson DE, Kandarpa M, Coakley AJ, Newman DJ, Saunders JA, Lamb EJ. Cystatin C improves the detection of mild renal dysfunction in older patients. Ann Clin Biochem. 2003 Nov;40(Pt 6):648-55.</citation>
    <PMID>14629803</PMID>
  </reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2007</study_first_submitted>
  <study_first_submitted_qc>April 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2007</study_first_posted>
  <last_update_submitted>May 6, 2008</last_update_submitted>
  <last_update_submitted_qc>May 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2008</last_update_posted>
  <keyword>Contrast-induced nephropathy</keyword>
  <keyword>Cystatin C</keyword>
  <keyword>Contrast media</keyword>
  <keyword>Creatinine</keyword>
  <keyword>Cardiac Catheterization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

